^
    Back
    Association details:
    Biomarker:HER-2 D769Y
    Cancer:HER2 Negative Breast Cancer
    Drug:lapatinib (EGFR inhibitor, HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    ASCO 2018
    Title:

    Impact of HER2 mutation status on personalized molecular targeted therapy in advanced breast cancers.

    Published date:
    05/16/2018
    Excerpt:
    There were three cases identified where HER2 mutation status impacted the selection of personalized anti-HER2 therapies….Case 3 was a HER2-negative breast cancer patient with two detected mutations in ERBB2 (p.S310F and p.D769Y mutations) who benefited from lapatinib combined with endocrine therapies.
    DOI:
    10.1200/JCO.2018.36.15_suppl.1039